Covered recipient · General Payments record
RICHARD B POWELL
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$39.93
2 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $39.93 | 2 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Vanda Pharmaceuticals Inc. | $28.82 | 1 |
| Amarin Pharma Inc. | $11.11 | 1 |
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RICHARD B POWELL
NPI 1023103702 · CMS profile ID 819362
Allopathic & Osteopathic Physicians / Internal Medicine
NEW PORT RICHEY, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- RICHARD B POWELL, NPI 1023103702, CMS profile ID 819362, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1023103702?year=2020&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
2 matching records · $39.93 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–2 of 2.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | $28.82 | 06/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735141111 | CMS |
| Amarin Pharma Inc. | $11.11 | 01/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740008645 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2023
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $123,379.85 | 19 |
| PY2024 | Principal investigator | $519,613.32 | 181 |
| PY2023 | Principal investigator | $3,705,517.67 | 2,390 |
| PY2022 | Principal investigator | $2,801,811.98 | 590 |
| PY2021 | Principal investigator | $422,228.81 | 39 |
| PY2020 | Principal investigator | $83,061.46 | 21 |
| PY2019 | Principal investigator | $408,254.19 | 140 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
590 records in PY2022
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca UK Limited | $13,125.48 | 12/31/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease | No dispute reported | 06/30/2026 | 914594825 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $3,772.00 | 12/27/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218313 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $31,720.92 | 12/26/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | CIMRD005476 | No dispute reported | 06/30/2026 | 915609953 |
| Principal investigator 1 | Bavarian Nordic A/S | $17,062.90 | 12/21/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967351 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $12,503.00 | 12/16/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218317 |
| Principal investigator 1 | Bavarian Nordic A/S | $6,820.40 | 12/14/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967311 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,585.00 | 12/08/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967379 |
| Principal investigator 1 | Bavarian Nordic A/S | $35,943.10 | 12/06/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967277 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,518.48 | 12/06/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967391 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $7,360.00 | 12/05/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218321 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,051.77 | 12/01/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967385 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,299.00 | 11/21/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230065 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194983 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194985 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194987 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963194989 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195295 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195297 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195299 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195765 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195767 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195769 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195771 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195773 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195775 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195777 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196087 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196089 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196091 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196093 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196303 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199537 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199539 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199541 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199543 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199545 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199757 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199759 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199761 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199763 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199765 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199767 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199769 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199771 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200225 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200227 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200229 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200231 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200233 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200581 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200583 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200585 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200587 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200589 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200591 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200593 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200595 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200597 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200895 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200897 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200899 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200901 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200903 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200905 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201225 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201227 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201229 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201231 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201233 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201235 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201237 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201239 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201557 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201559 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201561 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201563 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201565 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201567 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201569 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202021 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202023 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202025 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202027 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202029 |
| Principal investigator 1 | ModernaTX, Inc. | $538.25 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202031 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202033 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202035 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202037 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202367 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202369 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202371 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202585 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202587 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202589 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202739 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202741 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202743 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202745 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202747 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202749 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202751 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202753 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202961 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202963 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202965 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202967 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202969 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202971 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203337 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203339 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203341 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203343 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203345 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203347 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203349 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203781 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203783 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203785 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203787 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203789 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204135 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204137 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204139 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204141 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204143 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204145 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204147 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204149 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204151 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204153 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204155 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204463 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204465 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204467 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204469 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204471 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204473 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204475 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204477 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204765 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204767 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204769 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204771 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204773 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204775 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204777 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204779 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204781 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205217 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205219 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205221 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205223 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205225 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205227 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205515 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205517 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205519 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205521 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205523 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205525 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205527 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205529 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205531 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205533 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205535 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205537 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205539 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205797 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205799 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205801 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205803 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205805 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205807 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205809 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205811 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205813 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205815 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206249 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206251 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206253 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206255 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206257 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206259 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206261 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206263 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206265 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206267 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206579 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206583 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206587 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206591 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206595 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206599 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206603 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206607 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207203 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207207 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207211 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207215 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207955 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207959 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207963 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207967 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207971 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207975 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207979 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208567 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208571 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208575 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208579 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208837 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208841 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208845 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208849 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209265 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209269 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209273 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209277 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209281 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209285 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209289 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209293 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209679 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209681 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209683 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209837 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209839 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210041 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210043 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210045 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210047 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210049 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210547 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210549 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210551 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210553 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210833 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210835 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210837 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211217 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211219 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211221 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211223 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211427 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211429 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211431 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211433 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211435 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211437 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211439 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211441 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211443 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211445 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211447 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211597 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211599 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211601 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211603 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211919 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211921 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211923 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211925 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211927 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211929 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211931 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211933 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212247 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212249 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212251 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212253 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212255 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212599 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212601 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212603 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212605 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212607 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212879 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212881 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212883 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212885 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212887 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213297 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213299 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213301 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213653 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213655 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213657 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213659 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213661 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213663 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213665 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213667 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213669 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214099 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214101 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214103 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214105 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214107 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214409 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214411 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214413 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214415 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214417 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214419 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214421 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214423 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214685 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214687 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214689 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214691 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214693 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214695 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215253 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215259 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215265 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215269 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215275 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215281 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215287 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215291 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215297 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215303 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215309 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215315 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216133 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216141 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216147 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216149 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216151 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216153 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216155 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216157 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216159 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216161 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216163 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216529 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216531 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216533 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216535 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216537 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216539 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216541 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216543 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216545 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216547 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216969 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216971 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216973 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216975 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217287 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217289 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217291 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217293 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217295 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217297 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217299 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217301 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217303 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217305 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217307 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217309 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217311 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217745 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217747 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217749 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217751 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217753 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217755 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217757 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218117 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218119 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218121 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218123 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218125 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218127 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218129 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218131 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218133 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218135 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218341 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218343 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218345 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218347 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218707 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218709 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218711 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218713 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219035 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219037 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219039 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219041 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219043 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219259 |
| Principal investigator 1 | ModernaTX, Inc. | $538.25 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219261 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219263 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219265 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219267 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219269 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219271 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219273 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219275 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 11/17/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219277 |
| Principal investigator 1 | Bavarian Nordic A/S | $16,746.70 | 11/15/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967323 |
| Principal investigator 1 | ModernaTX, Inc. | $4,254.81 | 11/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211205 |
| Principal investigator 1 | ABBVIE INC. | $1,722.10 | 11/09/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men | No dispute reported | 06/30/2026 | 889819763 |
| Principal investigator 1 | Bavarian Nordic A/S | $3,952.50 | 11/08/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967289 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 11/03/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195121 |
| Principal investigator 1 | ModernaTX, Inc. | $10,000.00 | 11/03/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202013 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 11/03/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214079 |
| Principal investigator 1 | Bavarian Nordic A/S | $5,341.40 | 11/02/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967271 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,339.20 | 10/26/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967367 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $1,921.00 | 10/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218325 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,212.00 | 10/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230063 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $53,829.44 | 10/25/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | CIMRD005476 | No dispute reported | 06/30/2026 | 915610015 |
| Principal investigator 1 | Bavarian Nordic A/S | $6,585.80 | 10/18/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967339 |
| Principal investigator 1 | PFIZER INC. | $637.88 | 10/14/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949784711 |
| Principal investigator 1 | ABBVIE INC. | $5,740.10 | 10/12/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men | No dispute reported | 06/30/2026 | 889814767 |
| Principal investigator 1 | Bavarian Nordic A/S | $17,082.00 | 10/12/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967305 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195107 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195407 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195409 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195729 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195731 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963195733 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963196067 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199513 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199515 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199887 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199889 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963199891 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200199 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200203 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200555 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963200881 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201683 |
| Principal investigator 1 | ModernaTX, Inc. | $726.57 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201685 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201687 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963201689 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202003 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202005 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202349 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202719 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963202721 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203073 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203075 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203309 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203311 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203313 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203315 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963203761 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204115 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963204435 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205203 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963205507 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206231 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206805 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963206809 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207439 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207909 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963207913 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963208821 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209465 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963209813 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210169 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210171 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210173 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210515 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963210517 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211179 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211181 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211559 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211561 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211563 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211889 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211891 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963211893 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212565 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212567 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212569 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212571 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212859 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963212861 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213271 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213273 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213275 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213277 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213623 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963213625 |
| Principal investigator 1 | ModernaTX, Inc. | $2,032.69 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214067 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214395 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214809 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963214811 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215167 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215173 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963215179 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216111 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216507 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216945 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216947 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963216949 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217407 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217721 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963217723 |
| Principal investigator 1 | ModernaTX, Inc. | $2,443.98 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218091 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218325 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218687 |
| Principal investigator 1 | ModernaTX, Inc. | $3,644.40 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218689 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963218691 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219015 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219017 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219019 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219233 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219235 |
| Principal investigator 1 | ModernaTX, Inc. | $12.15 | 10/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963219237 |
| Principal investigator 1 | Bavarian Nordic A/S | $7,112.80 | 10/07/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967283 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,481.52 | 10/07/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967397 |
| Principal investigator 1 | PFIZER INC. | $7,654.56 | 09/30/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949785023 |
| Principal investigator 1 | Bavarian Nordic A/S | $7,160.40 | 09/28/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967373 |
| Principal investigator 1 | PFIZER INC. | $15,947.00 | 09/24/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949785021 |
| Principal investigator 1 | AstraZeneca UK Limited | $23,198.50 | 09/22/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease | No dispute reported | 06/30/2026 | 914604643 |
| Principal investigator 1 | Bavarian Nordic A/S | $6,899.40 | 09/20/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967345 |
| Principal investigator 1 | Bavarian Nordic A/S | $17,450.50 | 09/15/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967329 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,795.20 | 09/14/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967317 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,795.20 | 09/09/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967299 |
| Principal investigator 1 | ABBVIE INC. | $19,363.40 | 09/08/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men | No dispute reported | 06/30/2026 | 889810379 |
| Principal investigator 2 | Bayer HealthCare Pharmaceuticals Inc. | $11,000.00 | 09/08/2022 | Non-covered Recipient Entity Velocity Clinical Research | Efficacy and Safety of Finerenone in Combination with SGLT2i | No dispute reported | 06/30/2026 | 932269565 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $29,798.44 | 09/05/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | CIMRD005476 | No dispute reported | 06/30/2026 | 915608699 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $5,514.00 | 08/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $750.00 | 08/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229981 |
| Principal investigator 1 | ModernaTX, Inc. | $498.00 | 08/26/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH - CINCINNATI | A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older | No dispute reported | 06/30/2026 | 963324443 |
| Principal investigator 1 | Bavarian Nordic A/S | $9,216.40 | 08/23/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967363 |
| Principal investigator 1 | Janssen Research & Development, LLC | $39,093.00 | 08/19/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229987 |
| Principal investigator 1 | Bavarian Nordic A/S | $5,135.70 | 08/17/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967333 |
| Principal investigator 1 | PFIZER INC. | $1,883.28 | 08/16/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949784719 |
| Principal investigator 1 | ABBVIE INC. | $7,170.40 | 08/10/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men | No dispute reported | 06/30/2026 | 889804783 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,919.70 | 08/09/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967295 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $1,848.00 | 08/03/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218083 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,839.90 | 08/02/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967265 |
| Principal investigator 1 | PFIZER INC. | $2,197.16 | 07/29/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949784355 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $47,354.00 | 07/22/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885218079 |
| Principal investigator 1 | Janssen Research & Development, LLC | $76,790.00 | 07/22/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229985 |
| Principal investigator 1 | Bavarian Nordic A/S | $6,737.90 | 07/21/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967357 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,613.30 | 07/08/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967403 |
| Principal investigator 1 | ABBVIE INC. | $589.00 | 07/07/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men | No dispute reported | 06/30/2026 | 889798687 |
| Principal investigator 1 | PFIZER INC. | $2,426.66 | 06/29/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949784209 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $22,167.00 | 06/20/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217851 |
| Principal investigator 1 | Janssen Research & Development, LLC | $70,824.00 | 06/17/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229805 |
| Principal investigator 1 | Janssen Research & Development, LLC | $70,824.00 | 06/17/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229893 |
| Principal investigator 1 | PFIZER INC. | $1,569.40 | 06/15/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949784193 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $1,848.00 | 06/10/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217847 |
| Principal investigator 1 | ABBVIE INC. | $5,303.60 | 06/08/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men | No dispute reported | 06/30/2026 | 889794149 |
| Principal investigator 1 | Bavarian Nordic A/S | $8,000.00 | 06/07/2022 | Non-covered Recipient Entity Velocity Clinical Research | NCT05238025 | No dispute reported | 06/30/2026 | 906967409 |
| Principal investigator 1 | PFIZER INC. | $2,511.04 | 05/27/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949749193 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $492.91 | 05/26/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH CINCINNATI | A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin | No dispute reported | 06/30/2026 | 904837471 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $81,995.00 | 05/20/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217843 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36,561.00 | 05/20/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229803 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36,561.00 | 05/20/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229891 |
| Principal investigator 1 | AstraZeneca UK Limited | $10,000.00 | 05/19/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH | A Phase 2, Randomised, Double-Blind, Placebo and Active Comparator-Controlled Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD5718 Given Orally Once Daily for Twelve Weeks in Adults with Moderate-to-Severe Uncontrolled Asthma | No dispute reported | 06/30/2026 | 914591149 |
| Principal investigator 1 | PFIZER INC. | $1,569.40 | 05/14/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949749889 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,360.00 | 05/13/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229801 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,360.00 | 05/13/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229889 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 05/11/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229799 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,000.00 | 05/11/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229887 |
| Principal investigator 1 | ABBVIE INC. | $23,457.00 | 05/05/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men | No dispute reported | 06/30/2026 | 889789931 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $39,651.00 | 04/25/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217839 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $33,643.40 | 04/25/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | CIMRD005476 | No dispute reported | 06/30/2026 | 915609231 |
| Principal investigator 1 | Janssen Research & Development, LLC | $91,482.00 | 04/22/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229797 |
| Principal investigator 1 | Janssen Research & Development, LLC | $91,482.00 | 04/22/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229885 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $2,520.00 | 04/20/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217835 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $13,457.36 | 04/11/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | CIMRD005476 | No dispute reported | 06/30/2026 | 915608501 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,400.00 | 04/06/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229795 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,400.00 | 04/06/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229883 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $711.00 | 03/28/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217467 |
| Principal investigator 1 | Janssen Research & Development, LLC | $46,929.00 | 03/25/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229741 |
| Principal investigator 1 | Janssen Research & Development, LLC | $46,929.00 | 03/25/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230017 |
| Principal investigator 1 | Roche Diagnostics Operations, Inc. | $30,759.68 | 03/24/2022 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | CIMRD005476 | No dispute reported | 06/30/2026 | 915609523 |
| Principal investigator 1 | Janssen Research & Development, LLC | $364,377.00 | 03/23/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229739 |
| Principal investigator 1 | Janssen Research & Development, LLC | $364,377.00 | 03/23/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230015 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $41,143.00 | 03/18/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217463 |
| Principal investigator 1 | PFIZER INC. | $5,697.04 | 03/16/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949784511 |
| Principal investigator 1 | PFIZER INC. | $24,455.30 | 02/25/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949784179 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $27,665.00 | 02/16/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217459 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,373.00 | 02/16/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229737 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,373.00 | 02/16/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230013 |
| Principal investigator 1 | PFIZER INC. | $29,409.85 | 02/04/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949784359 |
| Principal investigator 1 | Janssen Research & Development, LLC | $48,538.00 | 01/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885229735 |
| Principal investigator 1 | Janssen Research & Development, LLC | $48,538.00 | 01/26/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of Ad26.COV2.S for the Prevention of SARSCoV2 Mediated COVID19 in Adult Participants | No dispute reported | 06/30/2026 | 885230011 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $60.83 | 01/26/2022 | Non-covered Recipient Entity NEW HORIZONS CLINICAL RESEARCH | A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCO | No dispute reported | 06/30/2026 | 909410117 |
| Principal investigator 1 | Janssen Pharmaceuticals, Inc | $25,635.00 | 01/21/2022 | Non-covered Recipient Entity Velocity Clinic Research, Inc. | A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older | No dispute reported | 06/30/2026 | 885217455 |
| Principal investigator 1 | PFIZER INC. | $8,781.75 | 01/08/2022 | Non-covered Recipient Entity Velocity Clinical Research | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 949784207 |